Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of upadacitinib in adults and adolescents with non-segmental vitiligo
2023-506195-27-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in Vitiligo comparing Upadacitinib with Placebo (2 arms). Primary endpoints: Achievement of T-VASI 50 at Week 48 and Achievement of F-VASI 75 at Week 48. Planned start Apr 2024; status: authorised.
02
Drugs
upadacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2023-506195-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506195-27-00.